Table 3 Correlations between imaging measures and clinical variables using a multiple comparison permutation method.

Whole SNc	Volume (mm³)	C_vol	CNR
	p	r	p	r	p	r
Healthy Controls
MDS-UPDRS-III OFF	0.304	0.089	0.379	0.047	0.022	− 0.350
Asymptomatic LRRK2 Carriers
MDS-UPDRS-I OFF	0.010	− 0.596	0.106	− 0.355	0.210	− 0.225
MDS-UPDRS-II OFF	0.048	− 0.444	0.032	− 0.479	0.149	0.223
MDS-UPDRS-III OFF	0.256	− 0.177	0.032	− 0.529	0.244	0.177
Patients with PD
MDS-UPDRS-I OFF	0.271	− 0.123	0.316	− 0.102	0.034	− 0.423
MDS-UPDRS-II OFF	0.310	− 0.091	0.249	− 0.153	0.249	− 0.201
MDS-UPDRS-III OFF	0.012	− 0.474	0.011	− 0.473	0.311	0.110
MDS-UPDRS-IV OFF	0.402	− 0.033	0.515	0.039	0.106	0.265
H&Y score	0.469	0.020	0.423	0.044	0.194	− 0.180
Disease Duration	0.226	− 0.157	0.277	− 0.127	0.323	− 0.093
Levodopa Equivalent Dose	0.336	0.107	0.220	0.174	0.386	0.065

CNR, Contrast to Noise Ratio; C_vol, Corrected volume; H&Y score, Hoehn and Yahr scale; HCs, Healthy controls; LRRK2, leucine-rich repeat kinase 2; PD, Parkinson’s disease; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale.
*indicates significant p values < 0.05 and # indicates trending p values between 0.05 and 0.09.

Quick links

Search